GET THE APP

Stem Cell Transplantation Impact Factor | Open Access Journals
..

Journal of Blood & Lymph

ISSN: 2165-7831

Open Access

Stem Cell Transplantation Impact Factor

Hematopoietic stem cell transplantation (GCSH) is now an established treatment for a number of non-malignant and malignant conditions. Allogeneic CTS derived from bone marrow or peripheral blood from a sibling identical to HLA cures more than half of patients with severe aplastic anemia, thalassemia major, congenital immunodeficiency diseases and genetic metabolic disorders. Among the malignancies, acute and chronic leukemia, multiple myeloma, Hodgkin's and non-Hodgkin's lymphoma, and high-risk neuroblastoma are important conditions that can be treated with HSCT. The main morbidities associated with GCSH are diet-related toxicities, the development of acute or chronic graft-against-host disease (GVHD), failure of the bone marrow transplant and complications related to immunodeficiency that occurs in the post-transplant period. Peripheral blood stem cells are now used as an alternative to bone marrow stem cells for allogenic GCSH and exclusively for autologous GCSH. Reduced intensity conditioning for allogenic GCSH resulted in lower frequency and severity of GVHD and a risk of infections. This has resulted in allogenic GCSH in older patients and in those with comorbidities.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

Google Scholar citation report
Citations: 443

Journal of Blood & Lymph received 443 citations as per Google Scholar report

Journal of Blood & Lymph peer review process verified at publons

Indexed In

 
arrow_upward arrow_upward